Featured Research

from universities, journals, and other organizations

Second Pathway Behind HIV-associated Immune System Dysfunction Identified

Date:
October 3, 2007
Source:
Massachusetts General Hospital
Summary:
Researchers may have discovered a second molecular 'switch' that turns off the immune system's response against HIV. Last year the same team identified a molecule that suppresses the activity of HIV-specific CD8 T cells that should destroy virus-infected cells. Now they describe how a regulatory protein called CTLA-4 inhibits the action of HIV-specific CD4 T cells that control the overall response against the virus.

Researchers at the Partners AIDS Research Center at Massachusetts General Hospital (PARC-MGH) may have discovered a second molecular "switch" responsible for turning off the immune system's response against HIV. Last year members of the same team identified a molecule called PD-1 that suppresses the activity of HIV-specific CD8 T cells that should destroy virus-infected cells. Now the researchers describe how a regulatory protein called CTLA-4 inhibits the action of HIV-specific CD4 T cells that control the overall response against the virus.

"We've shown that a known regulator of the immune system, CTLA-4, is present in elevated levels on the virus-specific CD4 cells that should be managing the body's response against HIV, says Daniel Kaufmann, MD, of PARC and the MGH Infectious Disease Unit, a co-first author of the recently published article. "We also found that CTLA-4 expression rises as HIV infection progresses and that the molecule switches off CD4 cell function in a way that appears to be reversible."

Expression of the CTLA-4 protein is known to be elevated on activated T cells, those that have encountered a pathogen and are multiplying rapidly to mount an immune response. Studies in cancer patients have shown that the molecule serves to dampen the immune response, and some preliminary investigations in animals and humans have suggested a potential role in HIV infection. The current study was designed to examine how CTLA-4 may be involved in the dysfunction of HIV-specific T cells that leads to the immune-system breakdown of AIDS.

The researchers first found that CTLA-4 was overexpressed on the HIV-specific CD4 T cells of infected individuals who had not yet received antiviral treatment. Levels were highest in those with symptoms of acute infection and second highest in chronically infected participants. CTLA-4 expression was lowest among a group of participants whose immune systems were naturally able to suppress HIV replication without antiviral medications -- "elite controllers" in whom viral levels are too low to be detected.

Elevated CTLA-4 expression also correlated with signs of disease progression -- increased viral load and reduced overall CD4 count. While antiviral treatment caused viral loads to drop significantly after treatment began, it resulted in only modest and slow drops in CTLA-4 expression. In vitro tests of the effects of blocking the CTLA-4 molecule improved the function of HIV-specific CD4 cells. Comparing the effects of blocking CTLA-4 with those of blocking PD-1 or both molecules produced functional improvements that varied considerably between participants, signifying a complex relationship between the pathways controlled by the two molecules.

"Both of these pathways contribute to dysfunction of HIV-specific T cells and both may be considered targets for therapeutic intervention. But since their mechanisms are so complicated, further study is needed before clinical trials can be planned," says Kaufmann, an instructor in Medicine at Harvard Medical School (HMS).

"Understanding why the immune system fails to control HIV is essential for development of vaccines and new therapies" said Bruce Walker, MD, director of PARC-MGH and senior author of the study. "These studies suggest that the immune system is turning itself off prematurely in HIV-infected persons, and the big challenge now is to figure out if we can turn it back on, getting it to do what it is supposed to do, without causing collateral damage in the process." Walker is a professor of Medicine at HMS and a Howard Hughes Medical Institute (HHMI) investigator.

The report will appear in the journal Nature Immunology and is receiving early online release.

Co-first author of the Nature Immunology report is Daniel Kavanagh, PhD, also of PARC and MGH. Additional co-authors are Florencia Pereyra, MD, Elizabeth Mackey, Toshiyuki Miura, PhD, DM; Mark Brockman, Almas Rathod, Alicja Piechocka-Trocha, Brett Baker, Sylvie Le Gall, PhD, Michael Waring, Ryan Ahern, Kristen Moss, and Eric Rosenberg, MD, of PARC-MGH; John Zaunders and Anthony Kelleher, MBBS, PhD, St. Vincent's Hospital, Darlington, NSW, Australia; Sarah Palmer, PhD, and John Coffin, PhD, National Cancer Institute; Baogong Zhu, MD, and Gordon Freeman, PhD, Dana-Farber Cancer Institute. External support for the study came from the National Institutes of Health, HHMI and the Mark and Lisa Schwartz Foundation.


Story Source:

The above story is based on materials provided by Massachusetts General Hospital. Note: Materials may be edited for content and length.


Cite This Page:

Massachusetts General Hospital. "Second Pathway Behind HIV-associated Immune System Dysfunction Identified." ScienceDaily. ScienceDaily, 3 October 2007. <www.sciencedaily.com/releases/2007/09/070930144552.htm>.
Massachusetts General Hospital. (2007, October 3). Second Pathway Behind HIV-associated Immune System Dysfunction Identified. ScienceDaily. Retrieved October 20, 2014 from www.sciencedaily.com/releases/2007/09/070930144552.htm
Massachusetts General Hospital. "Second Pathway Behind HIV-associated Immune System Dysfunction Identified." ScienceDaily. www.sciencedaily.com/releases/2007/09/070930144552.htm (accessed October 20, 2014).

Share This



More Health & Medicine News

Monday, October 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

How Nigeria Beat Its Ebola Outbreak

How Nigeria Beat Its Ebola Outbreak

Newsy (Oct. 20, 2014) The World Health Organization has declared Nigeria free of Ebola. Health experts credit a bit of luck and the government's initial response. Video provided by Newsy
Powered by NewsLook.com
Another Study Suggests Viagra Is Good For The Heart

Another Study Suggests Viagra Is Good For The Heart

Newsy (Oct. 20, 2014) An ingredient in erectile-dysfunction medications such as Viagra could improve heart function. Perhaps not surprising, given Viagra's history. Video provided by Newsy
Powered by NewsLook.com
Ebola Worries End for Dozens on U.S. Watch Lists

Ebola Worries End for Dozens on U.S. Watch Lists

Reuters - US Online Video (Oct. 20, 2014) Forty-three people who had contact with Thomas Eric Duncan, the first person diagnosed with Ebola in the U.S., were cleared overnight of twice-daily monitoring after 21 days of showing no symptoms. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com
Fauci: Ebola Protocols to Focus on Training

Fauci: Ebola Protocols to Focus on Training

AP (Oct. 20, 2014) Dr. Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases, says he expects revised CDC protocols on Ebola to focus on training, observation and ensuring health care workers are more protected. (Oct. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins